Sequencing Radium-223 and Docetaxel in Prostate CancerSequencing Radium-223 and Docetaxel in Prostate Cancer

A prespecified analysis of the ALSYMPCA data suggests radium-223 can be used in sequence with docetaxel in metastatic castration-resistant prostate cancer. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news